London, UK, 21 December 2022 – George Medicines announces that, Stefan König, Chief Executive Officer, will leave the Company at the end of the year to pursue a leadership position in a large biopharmaceutical organisation.
Stefan joined George Medicines as CEO in June 2021 and, during his tenure, has overseen the company’s continued progress and the execution of its strategy, including advancement of a major Phase III programme for its lead candidate, GMRx2, as a first-line treatment for hypertension, and the prioritisation of its second candidate, GMRx4, which has advanced into Phase II clinical development for the first-line treatment of type 2 diabetes.
Staph Leavenworth Bakali, President and CEO of George Health, and Board Director of George Medicines, has been appointed Acting CEO of George Medicines.
Stefan König, CEO of George Medicines, said: “It has been my absolute privilege to serve as CEO of George Medicines and I am incredibly proud of what the Company has achieved during this time. Its mission, to extend and improve the lives of those suffering from the world’s leading causes of death and disability, with an unwavering focus on global access, is truly inspiring. I have no doubt the team will continue to deliver and achieve great success.”
Stephen MacMahon, Chairman, George Medicines, said: “The Board would like to thank Stefan for his significant contribution and leadership during an important growth phase of the Company. We wish him every success in his new role. We are pleased to have Staph step into the Acting CEO role, to which he brings 30+ years of industry experience and an intimate knowledge and longstanding involvement with George Medicines. The Company is well positioned to achieving its near-term goals of successfully bringing GMRx2 to the market and helping to reduce the huge burden of hypertension on millions of patients as well as health systems.”
– Ends –
Contacts
George Medicines
Consilium Strategic Communications
David Daley, Lindsey Neville, Isabelle Abdou
Tel: +44 (0) 203 709 5700
georgemedicines@consilium-comms.com
About George Medicines
George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases (NCDs) with patented, innovative, multi-mechanism combinations of existing medicines given at ultra-low doses.
Combining best-in-class molecules from existing medicines in novel low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and accessible than currently available treatment options. These single-pill, multi-mechanism combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with NCDs, including hypertension, diabetes and other common cardiometabolic disorders, each of which remain the leading causes of premature death and disability worldwide.
The Company is building a strong and diversified pipeline of patented, single-pill, multi-mechanism combination therapies. Its lead candidate, GMRx2, is in Phase III development for the initial treatment of hypertension and under investigation for the prevention of recurrent intracerebral haemorrhage (the most severe type of stroke).
George Medicines is a spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm, supported by the Australian Government. For more information, please visit www.george-medicines.com.